Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with diabetes and established cardiovascular disease [1]. It is important to note that Ozempic is not indicated to alter meal portions. Instead, it works by mimicking the functions of natural hormones in the body to regulate blood sugar levels [2].

GLP-1 receptor agonists, like Ozempic, slow down gastric emptying, increase insulin secretion, and decrease glucagon secretion, ultimately leading to better glycemic control [3]. Although these mechanisms can affect appetite and food intake, the primary purpose of Ozempic is to help manage blood sugar levels, not to change meal portions.

In summary, while Ozempic can have an impact on appetite and food intake, it is not intended or approved to alter meal portions. The drug's primary function is to help regulate blood sugar levels in individuals with type 2 diabetes.

Sources:

[1] FDA. (2017). Highlights of Prescribing Information: Ozempic (semaglutide) injection. Retrieved from <https://www.fda.gov/media/108146/download>

[2] Novo Nordisk. (2021). Ozempic. Retrieved from <https://www.novonordisk-us.com/patient/products/ozempic.html>

[3] Drugs.com. (2021). Ozempic. Retrieved from <https://www.drugs.com/ozempic.html>

[4] DrugPatentWatch.com. (2021). Semaglutide. Retrieved from <https://www.drugpatentwatch.com/drugs/semaglutide>